Published in J Virol on October 01, 2004
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol (2010) 2.33
HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog (2007) 2.33
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science (2008) 2.23
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol (2006) 1.29
Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res (2011) 1.23
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog (2015) 1.18
Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology (2006) 1.17
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol (2005) 1.05
HIV latency: present knowledge, future directions. Future Virol (2006) 1.04
Picomolar dichotomous activity of gnidimacrin against HIV-1. PLoS One (2011) 1.01
Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One (2014) 0.99
Stelleralides A-C, novel potent anti-HIV daphnane-type diterpenoids from Stellera chamaejasme L. Org Lett (2011) 0.96
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Variability in content of the anti-AIDS drug candidate prostratin in Samoan populations of Homalanthus nutans. J Nat Prod (2008) 0.89
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors. J Virol (2006) 0.86
HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Front Immunol (2016) 0.81
Feline immunodeficiency virus latency. Retrovirology (2013) 0.81
Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter. Mol Ther (2016) 0.81
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function. Sci Rep (2016) 0.81
Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells. Virology (2015) 0.80
The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Sci Rep (2016) 0.78
A passive-flow microfluidic device for imaging latent HIV activation dynamics in single T cells. Integr Biol (Camb) (2015) 0.78
Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells. J Immunol (2014) 0.78
Prostratin exhibits both replication enhancing and inhibiting effects on FIV infection of feline CD4+ T-cells. Virus Res (2012) 0.76
The transposon-driven evolutionary origin and basis of histone deacetylase functions and limitations in disease prevention. Clin Epigenetics (2011) 0.75
In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation. Sci Rep (2016) 0.75
Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV. J Virol (2016) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
A quantitative assay for HIV DNA integration in vivo. Nat Med (2001) 8.67
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science (1991) 7.15
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med (1999) 4.32
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science (2001) 3.02
HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med (1999) 3.01
Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med (1983) 2.94
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature (2003) 2.90
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol (1995) 2.85
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med (1995) 2.31
Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell (1998) 2.23
Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science (1999) 2.21
Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med (1986) 2.17
Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.00
A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem (1992) 1.80
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Experimental HIV infection of human lymphoid tissue: correlation of CD4+ T cell depletion and virus syncytium-inducing/non-syncytium-inducing phenotype in histocultures inoculated with laboratory strains and patient isolates of HIV type 1. AIDS Res Hum Retroviruses (1997) 1.72
CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci U S A (1999) 1.67
Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat Med (1998) 1.62
Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue. J Virol (2000) 1.39
Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res (1997) 1.26
Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res (1993) 1.20
Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol (2003) 1.15
Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? J Med Chem (2000) 1.01
Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. Cancer Res (1991) 0.92
Segregation of R5 and X4 HIV-1 variants to memory T cell subsets differentially expressing CD62L in ex vivo infected human lymphoid tissue. AIDS (2002) 0.92
Non-promoting 12-deoxyphorbol 13-esters as potent inhibitors of phorbol 12-myristate 13-acetate-induced acute and chronic biological responses in CD-1 mouse skin. Carcinogenesis (1992) 0.92
Production of HIV-1 by resting memory T lymphocytes. AIDS (2001) 0.90
Truncated forms of human and simian immunodeficiency virus in infected individuals and rhesus macaques are unique or rare quasispecies. Virology (2003) 0.81
Extensively deleted simian immunodeficiency virus (SIV) DNA in macaques inoculated with supercoiled plasmid DNA encoding full-length SIVmac239. Virology (2001) 0.77
Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23
Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med (2007) 3.13
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg (2009) 2.57
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology (2008) 2.48
Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood (2007) 2.21
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood (2005) 2.21
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS (2006) 1.88
Zic2 patterns binocular vision by specifying the uncrossed retinal projection. Cell (2003) 1.81
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog (2009) 1.81
HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem Biophys Res Commun (2004) 1.80
Early prostate cancer--which treatment do men prefer and why? BJU Int (2010) 1.79
Mutations in the pre-replication complex cause Meier-Gorlin syndrome. Nat Genet (2011) 1.74
Characterisation of Upd2, a Drosophila JAK/STAT pathway ligand. Dev Biol (2005) 1.64
Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr (2006) 1.63
TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood (2004) 1.60
Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol (2006) 1.50
The red flour beetle's large nose: an expanded odorant receptor gene family in Tribolium castaneum. Insect Biochem Mol Biol (2007) 1.44
Exercise for dysmenorrhoea. Cochrane Database Syst Rev (2010) 1.43
A universal nanoparticle cell secretion capture assay. Cytometry A (2012) 1.41
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med (2011) 1.36
Synthetic peptidoglycan substrates for penicillin-binding protein 5 of Gram-negative bacteria. J Org Chem (2004) 1.33
A highly sensitive and dynamic immunofluorescent cytometric bead assay for the detection of HIV-1 p24. J Virol Methods (2009) 1.31
The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk. Sex Transm Dis (2012) 1.31
The fertile field of Drosophila Jak/STAT signalling. Curr Biol (2002) 1.30
Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network. J Infect Dis (2011) 1.29
Inhibition of HIV-1 replication in human lymphoid tissues ex vivo by measles virus. J Infect Dis (2005) 1.24
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol (2009) 1.23
A comparison of frequent and infrequent visitors to an urban emergency department. J Emerg Med (2008) 1.22
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol (2011) 1.19
HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood (2007) 1.19
CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J Virol (2011) 1.19
crossveinless-c is a RhoGAP required for actin reorganisation during morphogenesis. Development (2005) 1.19
Mutation spectrum in RAB3GAP1, RAB3GAP2, and RAB18 and genotype-phenotype correlations in warburg micro syndrome and Martsolf syndrome. Hum Mutat (2013) 1.17
In vitro analysis of partial loss-of-function ZIC2 mutations in holoprosencephaly: alanine tract expansion modulates DNA binding and transactivation. Hum Mol Genet (2004) 1.16
Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation (2005) 1.15
Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol (2003) 1.15
Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. J Infect Dis (2007) 1.15
Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA. J Mol Biol (2005) 1.13
Vpr and Vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo. J Virol (2004) 1.12
Loss-of-function mutations in TBC1D20 cause cataracts and male infertility in blind sterile mice and Warburg micro syndrome in humans. Am J Hum Genet (2013) 1.11
Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. Eur J Immunol (2011) 1.11
Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett (2005) 1.08
Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage (2010) 1.08
Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One (2009) 1.05
iCanCope with Pain™: User-centred design of a web- and mobile-based self-management program for youth with chronic pain based on identified health care needs. Pain Res Manag (2014) 1.05
Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. PLoS Pathog (2013) 1.05
Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol (2006) 1.04
Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem (2002) 1.04
B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J Immunol (2010) 1.03
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (2008) 1.03
Protein kinase A regulates caspase-1 via Ets-1 in bone stromal cell-derived lesions: a link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors. Hum Mol Genet (2010) 1.02
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr (2010) 1.02
Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am J Reprod Immunol (2011) 1.00
Activation of T lymphocytes in atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2011) 1.00
Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. J Virol (2005) 0.99
A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr (2012) 0.97
Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J Biol Chem (2003) 0.97
Contrasting roles for TLR ligands in HIV-1 pathogenesis. PLoS One (2010) 0.97
Epigenetic regulation of transcription and splicing of syncytins, fusogenic glycoproteins of retroviral origin. Nucleic Acids Res (2011) 0.96
Chronic nicotine in utero selectively suppresses hypoxic sensitivity in neonatal rat adrenal chromaffin cells. FASEB J (2007) 0.96
Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem (2005) 0.96
Stem cell regulation by JAK/STAT signaling in Drosophila. Semin Cell Dev Biol (2008) 0.96
A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. J Infect Dis (2010) 0.95
The Vif protein of human immunodeficiency virus type 1 is posttranslationally modified by ubiquitin. Biochem Biophys Res Commun (2004) 0.95
Validation of QF-PCR for prenatal aneuploidy screening in the United States. Prenat Diagn (2006) 0.95
Relationships between community characteristics and municipal smoke-free bylaw status and strength. Health Policy (2006) 0.93
Possible association of NTDs with a polyhistidine tract polymorphism in the ZIC2 gene. Am J Med Genet (2002) 0.93
Using an established telehealth model to train urban primary care providers on hypertension management. J Clin Hypertens (Greenwich) (2011) 0.92
Segregation of R5 and X4 HIV-1 variants to memory T cell subsets differentially expressing CD62L in ex vivo infected human lymphoid tissue. AIDS (2002) 0.92
Understanding the information and service needs of young adults with chronic pain: perspectives of young adults and their providers. Clin J Pain (2013) 0.92
A practical approach to genetic inducible fate mapping: a visual guide to mark and track cells in vivo. J Vis Exp (2009) 0.91
HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. Blood (2012) 0.91
A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent. J Org Chem (2004) 0.91
Skewed X chromosome inactivation and trisomic spontaneous abortion: no association. Am J Hum Genet (2009) 0.90
Radiation-induced skin injury in the animal model of scleroderma: implications for post-radiotherapy fibrosis. Radiat Oncol (2008) 0.90
Microarray assessment of methylation in individual mouse blastocyst stage embryos shows that in vitro culture may have widespread genomic effects. Hum Reprod (2011) 0.90
Hepatitis C virus fails to activate NF-κB signaling in plasmacytoid dendritic cells. J Virol (2011) 0.89
Immunolocalization of Zic2 expression in the developing mouse forebrain. Gene Expr Patterns (2003) 0.89
AJR teaching file: Intraventricular mass. AJR Am J Roentgenol (2007) 0.88
CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines. J Infect Dis (2004) 0.88